KDM4A Antibody

中文名稱：

KDM4A兔多克隆抗體
貨號：

CSB-PA012137LA01HU
規(guī)格：

￥440
圖片：
Immunohistochemistry of paraffin-embedded human testis tissue using CSB-PA012137LA01HU at dilution of 1:100

Immunohistochemistry of paraffin-embedded human brain tissue using CSB-PA012137LA01HU at dilution of 1:100

Immunofluorescent analysis of MCF-7 cells using CSB-PA012137LA01HU at dilution of 1:100 and Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L)
其他：

產(chǎn)品詳情
產(chǎn)品評價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

產(chǎn)品名稱：

Rabbit anti-Homo sapiens (Human) KDM4A Polyclonal antibody
Uniprot No.：

O75164
基因名：

KDM4A
別名：

JHDM3A antibody; JmjC domain containing histone demethylation protein 3A antibody; JmjC domain-containing histone demethylation protein 3A antibody; JMJD2 antibody; JMJD2A antibody; jumonji C domain containing histone demethylase 3A antibody; Jumonji domain containing 2 antibody; Jumonji domain containing 2A antibody; Jumonji domain containing protein 2A antibody; Jumonji domain-containing protein 2A antibody; KDM4A antibody; KDM4A_HUMAN antibody; KIAA0677 antibody; Lysine (K) specific demethylase 4A antibody; Lysine-specific demethylase 4A antibody; TDRD14A antibody; Tudor domain containing 14A antibody
宿主：

Rabbit
反應(yīng)種屬：

Human
免疫原：

Recombinant Human Lysine-specific demethylase 4A protein (127-364AA)
免疫原種屬：

Homo sapiens (Human)

標(biāo)記方式：

Non-conjugated

本頁面中的產(chǎn)品，KDM4A Antibody (CSB-PA012137LA01HU)，的標(biāo)記方式是Non-conjugated。對于KDM4A Antibody，我們還提供其他標(biāo)記。見下表：

標(biāo)記方式	貨號	產(chǎn)品名稱	應(yīng)用
HRP	CSB-PA012137LB01HU	KDM4A Antibody, HRP conjugated	ELISA
FITC	CSB-PA012137LC01HU	KDM4A Antibody, FITC conjugated
Biotin	CSB-PA012137LD01HU	KDM4A Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA, IHC, IF

推薦稀釋比：

Application	Recommended Dilution
IHC	1:20-1:200
IF	1:50-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價(jià)

靶點(diǎn)詳情

功能：

Histone demethylase that specifically demethylates 'Lys-9' and 'Lys-36' residues of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-4', H3 'Lys-27' nor H4 'Lys-20'. Demethylates trimethylated H3 'Lys-9' and H3 'Lys-36' residue, while it has no activity on mono- and dimethylated residues. Demethylation of Lys residue generates formaldehyde and succinate. Participates in transcriptional repression of ASCL2 and E2F-responsive promoters via the recruitment of histone deacetylases and NCOR1, respectively.; Crucial for muscle differentiation, promotes transcriptional activation of the Myog gene by directing the removal of repressive chromatin marks at its promoter. Lacks the N-terminal demethylase domain.
基因功能參考文獻(xiàn)：
1. MiR150 plays an important role in the development of lung cancer by serving as an oncogene via the SIRT2/JMJD2A signaling pathway. PMID: 29901178
2. Data show that lysine demethylase 4 A/B double tudor domains (KDM4A/B DTDs) bind strongly to histone H3 (H3)K23me3. PMID: 27841353
3. Generation of 2-hydroxyglutarate by mutated IDH1/2 leads to the activation of mTOR by inhibiting KDM4A. PMID: 27624942
4. The present study indicates a novel evidence for JMJD2A in tumorigenesis by upregulating miR372 in liver cancer cells. PMID: 28467776
5. JMJD2A regulated aerobic glycolysis by regulating LDHA expression. Therefore, the novel JMJD2A-LDHA signaling pathway could contribute to the Warburg effects in NPC progression. PMID: 28693517
6. Findings inidicate a unique breast cancer stem-like cells (BCSC) culture system for drug screening and offer preclinical proof of concept for lysine demethylase 4A (KDM4A) inhibition as a new strategy to treat triple-negative breast cancer. PMID: 28883001
7. The pyruvate dehydrogenase kinases (PDKs) PDK1 and PDK3 are direct targets of KDM4A and E2F1 and modulate the switch between glycolytic metabolism and mitochondrial oxidation. PMID: 27626669
8. results suggest that KDM4A possesses the potential to act as an oxygen sensor in the context of chromatin modifications, with possible implications for epigenetic regulation in hypoxic disease states PMID: 28051298
9. Here we show that JMJD2A, the first identified Jumonji C domain-containing histone demethylase, is the histone demethylase responsible for SUMO-2/3 enrichment on the Kaposi's sarcoma associated herpesvirus genome during viral reactivation PMID: 28212444
10. Lgr4 activates Jmjd2a/AR signaling pathway to promote interaction AR with PSA promoter, causing reduction of prostate cancer apoptosis and cell cycle arrest. PMID: 27743893
11. We demonstrate the previously unreported inhibitory action of PKF118-310 on KDM4A. Our findings open up the possibility of developing the first KDM4A-specific inhibitors and derivatives. PMID: 27767379
12. KDM4A downregulation promotes autophagy in glioma cell lines. PMID: 27514525
13. ERG promotes prostate tumorigenesis together with KDM4A through the upregulation of YAP1. A corollary is that KDM4A as well as YAP1 inhibitors may prove beneficial for the therapy of ERG-overexpressing prostate tumors. PMID: 27109047
14. In pancreatic neoplasms, miR-137 targets KDM4A mRNA during Ras-induced senescence and activates both p53 and retinoblastoma (pRb) tumor suppressor pathways. PMID: 26904954
15. Study demonstrates that JMJD2A contributes to tumorigenesis in non-small cell lung cancer (NSCLC) by regulating miR-150. Additionally, JMJD2A overexpression is associated with a poor prognosis for NSCLC patients. PMID: 26498874
16. High KDM4A expression is associated with endometrial cancer progression. PMID: 26397136
17. Studies indicate that histone lysine demethylase (JmjC-KDM) KDM4A protein has been implicated in numerous cancers and cardiovascular diseases. PMID: 25832587
18. KDM4A is regulated by hsa-mir-23a-3p, hsa-mir-23b-3p, and hsa-mir-137. PMID: 26755726
19. these data reveal a JMJD2A/ETV1/YAP1 axis that promotes prostate cancer initiation and that may be a suitable target for therapeutic inhibition. PMID: 26731476
20. Results indicate that SCF(Fbxo22)-KDM4A is an E3 ubiquitin ligase that targets methylated p53 and regulates key senescent processes. PMID: 26868148
21. This study showed that KDM4A interacts with RNA Polymerase I, associates with active ribosomal RNA genes and is required for serum-induced activation of rDNA transcription. PMID: 26729372
22. Jra recruits the HP1a/KDM4A complex to its gene body region upon osmotic stress to reduce H3K36 methylation levels and disrupt H3K36 methylation-dependent histone deacetylation PMID: 25945750
23. A coding single-nucleotide polymorphism in lysine demethylase KDM4A associates with increased sensitivity to mTOR inhibitors PMID: 25564517
24. KDM4 mediates nutrient-limitation signaling that leads to the transcriptional induction of autophagy. PMID: 25660547
25. this review focuses on describing the structure, mechanisms, and function of KDM4A and primarily discusses the role of KDM4A in cancer development and the importance of KDM4A as a potential therapeutic target. [review] PMID: 25633974
26. Negative regulation of Sp1 by JMJD2A causes downregulation of Sp1 in highly invasive breast cancer cells. PMID: 25193278
27. The data indicate that JMJD2A could promote breast cancer progression through transcriptional repression of the tumor suppressor ARHI. PMID: 24886710
28. JMJD2A is a promoter of endometrial carcinoma cell proliferation and survival, and is a potential novel drug target. PMID: 24815446
29. Those findings demonstrate that JMJD2A regulates gastric cancer growth and serves as an independent prognostic factor, and implicate that JMJD2A may be a promising target for intervention. PMID: 24802408
30. Findings demonstrate that KDM4A overexpression results in site-specific copy gain of regions amplified in human tumors. PMID: 23871696
31. analysis of the nickel-induced inhibition of truncated constructs of JMJD2A and JMJD2C histone demethylases using X-ray absorption spectroscopy PMID: 23692052
32. JMJD2A regulation has a role in human carcinogenesis through regulation of the G(1)/S transition PMID: 23603248
33. The expression of JMJD2A inhibits Ras-mediated CHD5 induction leading to a reduced activity of the p53 pathway. PMID: 23168260
34. overexpression of JMJD2A may contribute to breast tumor formation by stimulating ERalpha activity and that JMJD2A may be a breast-relevant oncoprotein. PMID: 22948256
35. data indicate that JMJD2A is a novel promoter of colon cancer cell proliferation and survival, which mediates its effects in p53-dependent and -independent ways PMID: 22134899
36. JMJD2A gene could result in cell cycle change and proliferation inhibition, and lead to suppress tumor cell invasion and migration. PMID: 21962223
37. JMJD2A and AR levels were significantly lower in malignant versus benign urothelium, while increased LSD1 levels were observed in malignant urothelium relative to benign; a significant reduction in all three proteins occurred with cancer stage progression PMID: 21400613
38. SKP1-Cul1-F-box and leucine-rich repeat protein 4 (SCF-FbxL4) ubiquitin ligase regulates lysine demethylase 4A (KDM4A)/Jumonji domain-containing 2A (JMJD2A) protein PMID: 21757720
39. these results demonstrate that SCF(FBXO22) regulates changes in histone H3 marks and cognate transcriptional control pathways by controlling KDM4A levels PMID: 21768309
40. The expression of JMJD2A was upregulated in human hypertrophic cardiomyopathy patients. PMID: 21555854
41. The authors show that knockdown of JMJD2A, an H3K9me3 demethylase, attenuates viral titers, whereas its overexpression increases Kaposi's sarcoma-associated herpesvirus reactivation. PMID: 21228229
42. JHDM3A(GFP)(701) is a suitable catalytic module that can be targeted, under the control of a guide protein, to specific loci where the chromatin H3K9me3 status and the milieu of gene expression are to be modified. PMID: 21148561
43. The ability of JMJD2A to associate with retinoblastoma proteins and histone deacetylase 1 implies an important role for this protein in cell proliferation and oncogenesis. PMID: 15927959
44. JMJD2A selectively represses the expression of the achaete scute-like homologue 2 (ASCL2) gene but not other imprinted genes in the same imprinted locus in HeLa cells PMID: 16024779
45. crystal structure of the double tudor domain of JMJD2A both in the presence and absence of a trimethylated H3-K4 peptide PMID: 16601153
46. JHDM3A may function in euchromatin to remove histone methylation marks that are associated with active transcription PMID: 16732292
47. identified two related histone demethylases, JMJD2A and JMJD2D PMID: 17555712
48. how human JMJD2A, which is selective towards tri- and dimethylated histone H3 lysyl residues 9 and 36 (H3K9me3/me2 and H3K36me3/me2), discriminates between methylation states and achieves sequence selectivity for H3K9 PMID: 17589501
49. Crystal structures of the JMJD2A catalytic domain in complex with H3K9me3, H3K36me2 and H3K36me3 peptides are presented. PMID: 17589523
50. Human JMJD2A was expressed in undifferentiated and differentiated ES cells. PMID: 17611647
顯示更多

收起更多
亞細(xì)胞定位：

Nucleus.
蛋白家族：

JHDM3 histone demethylase family
組織特異性：

Ubiquitous.
數(shù)據(jù)庫鏈接：

HGNC: 22978

OMIM: 609764

KEGG: hsa:9682

STRING: 9606.ENSP00000361473

UniGene: Hs.155983

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human